Literature DB >> 10865990

Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization.

A Kvanta1, S Sarman, P Fagerholm, S Seregard, B Steen.   

Abstract

Matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) are all implicated in the development of neovascularization. To investigate the possible role of these factors in corneal neovascularization we have analysed the expression of MMP-2, MMP-9 and VEGF in a rat model of inflammation-associated corneal neovascularization. In this model, corneal neovascularization was induced in Long-Evans rats by krypton laser photocoagulation whereafter eyes were enucleated at 1, 4, 7, 10 and 20 days. Slit-lamp biomicroscopy and histologic analysis revealed a gradual development of corneal neovascularization that peaked 7-10 days after treatment when newly formed vessels could be seen throughout the corneal surface reaching deep into the stroma. Antisense and sense riboprobes were generated using DNA complementary to MMP-2, MMP-9 and VEGF, and mRNA expression was analysed using in situ hybridization. The expression of MMP-2 and MMP-9 in untreated corneas was low or absent whereas VEGF was weakly expressed in the corneal epithelium. MMP-2 expression was increased during corneal neovascularization and was mainly localized to the cells infiltrating areas of new vessel formation. Many of these cells appeared to be inflammatory cells. VEGF expression had a similar overall distribution to MMP-2 during neovascularization with the exception that its expression in the corneal epithelium remained and even increased slightly. MMP-9 was prominently expressed at the border of regenerating corneal epithelium in areas with epithelial wounding but was not detected in the vascularized stroma. Together, the results of the present study support a role for MMP-2 and VEGF in inflammation-associated corneal neovascularization whereas MMP-9 instead appears to be involved in corneal epithelial wound-healing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10865990     DOI: 10.1006/exer.1999.0790

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  37 in total

Review 1.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

Review 2.  Wound healing fibroblasts modulate corneal angiogenic privilege: interplay of basic fibroblast growth factor and matrix metalloproteinases in corneal angiogenesis.

Authors:  Jin-Hong Chang; Kyu Yeon Han; Dimitri T Azar
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

3.  Effect of Rho-kinase Inhibitor, Y27632, on Porcine Corneal Endothelial Cell Culture, Inflammation and Immune Regulation.

Authors:  Whayoung Lee; Yuko Miyagawa; Cassandra Long; Matthew Zhang; David K C Cooper; Hidetaka Hara
Journal:  Ocul Immunol Inflamm       Date:  2015-10-16       Impact factor: 3.070

4.  Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR.

Authors:  Joshua M Barnett; Gary W McCollum; Jessica A Fowler; James J-W Duan; Jesse D Kay; Rui-Qin Liu; David P Bingaman; John S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-02       Impact factor: 4.799

5.  Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).

Authors:  Roberta P A Manzano; Gholam A Peyman; Palwasha Khan; Petros E Carvounis; Muhamet Kivilcim; Min Ren; Jonathan C Lake; Patricia Chévez-Barrios
Journal:  Br J Ophthalmol       Date:  2006-12-19       Impact factor: 4.638

6.  Time-dependent matrix metalloproteinases and tissue inhibitor of metalloproteinases expression change in fusarium solani keratitis.

Authors:  Qian Li; Xin-Rui Gao; Hong-Ping Cui; Li-Li Lang; Xiu-Wen Xie; Qun Chen
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

7.  Mesenchymal stem cells improve healing of the cornea after alkali injury.

Authors:  Diamantis Almaliotis; Georgios Koliakos; Eleni Papakonstantinou; Anastasia Komnenou; Angelos Thomas; Spiros Petrakis; Ilias Nakos; Eleni Gounari; Vasileios Karampatakis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-23       Impact factor: 3.117

8.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

Review 9.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

10.  Doxycycline-mediated inhibition of choroidal neovascularization.

Authors:  Sonia Samtani; Juan Amaral; Maria M Campos; Robert N Fariss; S Patricia Becerra
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-10       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.